Other languages Ascelia Pharma AB

Equities

ACE

SE0010573113

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 20/06/2024 pm IST			5-day change	1st Jan Change
9.47 ^SEK	+8.35%		+0.74%	+181.01%

17/06	Transcript : Ascelia Pharma AB - Special Call
21/05	Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
Ascelia Pharma AB Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study	02/05
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10/04
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	10/02
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	08/12
Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
OptiCept Technologies Names New CFO	20/23/20
Ascelia Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18
Ascelia Pharma AB Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE	08/23/08
Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Ascelia Pharma AB Announces Demise of René Spogárd, Member of the Board of Directors	13/23/13
Ascelia Pharma AB Announces the Decision of the US Patent and Trademark Office to Allow the Issuance of a Third Patent Covering the Composition of Oncoral	13/23/13
Ascelia Pharma Achieves Last Patient Last Visit in the Orviglance Phase 3 Sparkle Study Which Now Includes 85 Completed Patients	03/23/03
Ascelia Pharma AB Announces the Successful Completion of the Patient Enrollment in the Company's Pivotal Phase 3 Clinical Study Sparkle with the Lead Candidate Drug Orviglance	24/23/24
Ascelia Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/23/10
Ascelia Pharma AB Announces 71 Patients Have Completed the SPARKLE Study	27/23/27
Ascelia Pharma AB Announces 65 Patients Completes the Sparkle Study	29/22/29
Ascelia Pharma AB Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study	06/22/06
Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed	02/22/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ascelia Pharma AB

Equities

ACE

SE0010573113

Other languages

Filters